![](/img/cover-not-exists.png)
Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer
Pamela Taxel, Robert Dowsett, Lee Richter, Pamela Fall, Alison Klepinger, Peter AlbertsenVolume:
106
Year:
2010
Language:
english
Pages:
4
DOI:
10.1111/j.1464-410x.2010.09329.x
File:
PDF, 228 KB
english, 2010